Related Experiment Video
Updated: Jul 12, 2026
08:57
Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
Published on: May 17, 2024
BRAF(E600) in benign and malignant human tumours.
C Michaloglou1, L C W Vredeveld, W J Mooi
1Division of Molecular Genetics, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Oncogene
|August 29, 2007
Summary
The BRAF V600E mutation drives cancer proliferation but also triggers cellular senescence. Understanding this dual role of BRAF(V600E) is key for developing targeted cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- BRAF is a frequently mutated RAF kinase in human cancers.
- The V600E mutation leads to constitutive BRAF kinase activation.
- BRAF(V600E) is essential for the proliferation of tumor cells.
Purpose of the Study:
- To review recent advances in understanding BRAF(V600E) in human tumors.
- To discuss the implications of BRAF(V600E) signaling in cancer development and senescence.
- To explore therapeutic interventions targeting BRAF(V600E).
Main Methods:
- Review of recent studies on BRAF(V600E) in cultured cells.
- Analysis of animal models with BRAF(V600E) mutations.
- Examination of benign and malignant human lesions.
Main Results:
- BRAF(V600E) acts as an oncogene in conjunction with other genetic alterations.
- In primary cells, BRAF(V600E) initially stimulates proliferation transiently.
- BRAF(V600E) signaling ultimately induces cell cycle arrest and cellular senescence.
Conclusions:
- BRAF(V600E) plays a complex role in both tumor progression and senescence.
- Targeting BRAF(V600E) offers therapeutic potential for various human tumors.
- Further research is needed to fully elucidate BRAF(V600E) signaling pathways for effective treatment strategies.
